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Introduction
Results of clinical trials of certain drugs, such as aspirin (1) and tamoxifen (2) , provide proof of principle that cancer chemoprevention is a viable option to reduce cancer incidence. Nevertheless, the requirement of long-term intervention in cancer chemoprevention and concerns about the safety on long-term use of such drugs in relatively healthy humans (3, 4) render the search for safe and efficacious agents highly propitious. Edible plants constitute an attractive source of novel potential cancer chemopreventive agents, as the safety record of dietary constituents tends to be good. Flavonoids, exemplified by the flavonols quercetin in onions and apples and epigallocatechin-3 gallate in tea and the isoflavone genistein in soya, are examples of phytochemicals with suspected cancer chemopreventive properties (5) (6) (7) . Very little information exists as to molecular features which confer pharmacological activity on to the flavonoid scaffold. Such knowledge is required to help the rational discovery, or chemical design, of flavonoids with optimal cancer chemopreventive efficacy. Recent evidence suggests that the presence of methoxy moieties instead of, or in addition to, hydroxy in certain flavonoids augments cancer chemopreventive activity (8, 9) . Prominent among the many mechanisms via which flavonoids are thought to exert their chemopreventive activity is activation of wildtype p53 (10) and/or down-regulation of its mutant counterpart (11). The tumor suppressor protein p53 is involved in DNA damage repair, cell cycle arrest and apoptosis through transcriptional regulation of genes implicated in these pathways and by direct interaction with other proteins (12, 13) . P53-inactivating mutations are present in more than 50% of all cancers, including colon cancer, leading to 4 aggressive, treatment-resistant malignancies (14, 15) . Small molecules, such as CP-31398, a styrylquinazoline from Pfizer, have been designed to target p53 and to restore its growth suppressor function. CP-31398 reduced the growth of human colon tumor xenografts in nude mice (16) and potently compromised adenoma development in the Apc Min mouse, accompanied by a marked increase in adenomatous p53 levels (17) . The Apc Min mouse is a model of colorectal carcinogenesis associated with an Apc mutation (18) , and this model is frequently used in the preclinical identification of candidate colorectal cancer chemopreventive agents for clinical development.
Flavonols, exemplified by quercetin (3',4',5,7-tetrahydroxyflavonol), have been arguably the focus of more pharmacological investigations than most other flavonoids. Quercetin has shown cancer chemopreventive properties in rodent models of carcinogenesis of the colon, mouth, cervix and lung (5, (19) (20) (21) , and it has been subjected to a phase 1 clinical trial in cancer patients (22) . Its des-hydroxy cogener fisetin (3',4',7-trihydroxyflavonol, for structures see fig. 1 ) has recently been found to possess preclinical prostate cancer chemopreventive activity (23) . However, a serious toxicological impediment of many flavonols, which militates against their development as cancer chemopreventive agents, is their mutagenicity. Quercetin (24) (25) (26) and, to a lesser extent, fisetin (27) , were shown to be mutagenic in the Ames test. There is also limited evidence for the carcinogenicity of quercetin in animals (28,29). These toxicological properties of quercetin militate against its further clinical development. Toxicophoric structural features considered responsible for the mutagenic potential of flavonols include phenolic hydroxy moieties in both the A and B rings of the molecular scaffold (24, 26, 27) . of tumor p53 expression. We also measured TMFol levels in murine target tissues, to relate activity to presence of pharmacologically active agent. The potential mutagenicity of TMFol was investigated in the Ames reverse mutation assay using a panel of Salmonella Typhimurium strains, in which quercetin has shown mutagenic activity (24) (25) (26) (27) . Overall the work was designed to discover safe and efficacious cancer chemopreventive agents structurally based on pharmacologically interesting plant constituents. 
Materials and Methods
Chemicals and reagents
TMFol, synthesized as described previously (32) values were calculated from a plot of cell number at day 6 (percentage of vehicle control) versus agent concentration, using the linear phase of the curve.
Animals and TMFol dose
Breeding colonies were established using C57BL/6J Min/+ (Apc Min ) mice originally obtained from the Jackson Laboratory (Bar Harbor, ME). Ear tissue from newborn mice was genotyped for the presence of the mutation, using PCR as described previously (33) . 
Western blot analysis
Tumor tissue from control mice or mice which received TMFol was homogenized with lysis buffer (1:4, w:v. PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, with protease inhibitors PMSF 1mM, aprotinin 2µg/ml, leupeptin 5µg/ml and phosphatase inhibitors sodium vanadate 1mM and sodium fluoride 1mM). The homogenate was placed on ice (15min) and then centrifuged (20min, 10,000xg, 4ºC). Cells were grown to 60-80% confluency, followed by exposure for 72h to TMFol. Cells were centrifuged (5min, 10,000xg, 4ºC), and the cell pellet was suspended in lysis buffer. Protein concentration in tissue or cell lysate was determined using the Biorad protein assay (Biorad, Hemel Hempstead, UK) with bovine serum albumin as standard. An aliquot of protein lysate (50µg) was separated by SDS-PAGE and transferred for 1h onto a nitrocellulose membrane (Schleicher & Schuell, NH, USA). Blots were blocked for 2h with 5% skimmed milk in PBS/Tween 0.05% (PBS-T), and probed with a specific primary antiserum in PBS containing 0.05% PBS-T and 5% non-fat dry milk (4ºC, overnight). After washing (PBS-T), blots were treated with horseradish peroxidase-conjugated secondary antibody for 1h and washed (5X for 5min) in PBS-T. Proteins were detected by the enhanced chemiluminescence system (Geneflow, Staffordshire, UK).
HPLC analysis
Tissue sample preparation and HPLC analysis using fluorescence detection were as described before (32) 
Reverse mutation assay
The Ames test was conducted at a facility operating to GLP conditions by Safepharm Laboratories (Shardlow, Derbyshire, UK). Samonella strains TA100, 102
and 98, obtained from the University of California at Berkeley, were exposed to TMFol dissolved in DMSO using the Ames plate incorporation method at 5 dose levels, both with and without a rat liver homogenate metabolism system (10% liver S9 with standard co-factors). The dose range for the experiment (50-5000µg/plate) was determined in a preliminary toxicity assay. Aliquots (0.1ml) of bacterial culture were dispensed into test tubes followed by molten trace histidine-supplemented top (Fig. 2A) .
Total adenoma number was not significantly reduced by TMFol, however when the proximal subsection of the small intestine was considered separately, TMFol decreased both adenoma number and burden ( (Fig. 3B) .
Proliferation was not reduced in tumors from mice on the TMFol late regimen. Tumor levels of apoptotic cells were elevated by 55% compared to control animals in tumors from mice on the TMFol early regimen, whilst there was no increase in apoptosis in tumors from mice on the TMFol late regimen (Fig. 3C) .
Effect of TMFol on p53 expression in tumors
In adenomas from Apc Min mice, which had consumed TMFol, tissue expression of p53 was about three times the level observed in control mice (Fig. 4A) .
Similarly, p53 expression in tumor tissue from HCT116 tumor-bearing mice on the TMFol early regimen was increased by 50% over expression in controls (Fig. 4B) . In contrast, p53 expression was not significantly increased over controls in tumors from mice on the TMFol late regimen. Expression of p53 was also up-regulated in APC10.1 and HCT116 tumor cells in vitro, when exposed for 72h to TMFol at 5 or 10µM, respectively, compared to cells in control incubations (Fig. 4C,D) . In preliminary experiments, HCT116 cells exposed to TMFol showed biochemical changes fully consistent with p53 upregulation: TMFol at 10µM significantly increased expression of p53, p21 and Bax genes in HCT116 cells, as measured by RTPCR analysis, and it increased the expression of the p53 target proteins p21 and Bax 4-and 2-fold, respectively, in HCT116 cells transfected with suitable luciferase constructs (results not shown).
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Analysis of TMFol levels in tumor tissue
We wished to relate the observed efficacy of TMFol to retard tumor development in the mouse models with agent levels achieved in the target tissues.
HCT116 tumour tissue was obtained from nude mice at the end of the efficacy experiment described in Fig. 3 and subjected to HPLC analysis (Fig. 5) . Tumor levels of TMFol were 146±80pmoles/g tissue (mean±SD, n=6 mice), 146nM in molar concentration terms. We have reported previously that the concentration of TMFol in the gastrointestinal mucosa of C57BL6/J mice, the Apc Min background strain, which received TMFol for a week at the same dietary dose as that used in the Apc Min mice described here, was 220±68nmoles/g tissue, 220µM in concentration terms (32) .
TMFol levels in the Apc Min mice in the present study were probably of a similar order of magnitude. The large difference in TMFol levels between xenograft tumor and murine gut reflects agent available in tissue via the circulation in the former and mainly unabsorbed TMFol in the latter tissue.
Lack of mutagenicity of TMFol in the Ames test
TMFol was subjected to the Ames reverse mutation assay in order to establish its mutagenic potential in vitro. Salmonella strains TA100, 102 and 98 were tested, the two former indicating base-pair substitution mutations and the latter frameshift mutations. TMFol at concentrations of up to 5mg/plate failed to cause any visible increase in the frequency of revertant colonies either in the presence or absence of rat hepatic metabolic activating enzymes in any of the bacterial incubations (Table 1 ). In contrast, suitable model mutagens, both direct acting genotoxicants and chemicals requiring metabolic activation, caused expected 16 revertant colony increases. These results demonstrate that TMFol at the concentrations employed is not mutagenic in this system.
Discussion
The results described above provide proof of principle that judicious structural modification of the quercetin molecular scaffold can generate compounds which lack mutagenic activity in vitro and interfere with colorectal carcinogenesis in mice in vivo.
Whilst quercetin has shown chemopreventive properties in some preclinical models of oral, cervical, lung and colon carcinogenesis (5, (19) (20) (21) , it was devoid of the ability to prevent adenoma development in the Apc Min mouse (36) . Quercetin at dietary concentrations of 0.3-3% has even been demonstrated to augment, rather than counteract, azoxymethane-induced formation of colonic aberrant crypts and adenocarcinomas in rodents (37, 38) . Furthermore, the mutagenicity of quercetin (24- 
Apc
Min and HCT116 xenograft models as described here, remain to be elucidated.
On the basis of the literature pertaining to the p53-modulating effects of CP-31398
(cited in 17), these mechanisms are likely to be complex and model-dependent. It is worth emphasising that TMFol is likely to engage anti-carcinogenic mechanisms other than p53 modulation, and these mechanisms need to be identified in future studies.
The mutagenic activity of flavonols has been associated with hydroxy moieties in rings A and B of the molecular scaffold (24, 25) , and their methylation decreased mutagenic activity (24, 27) . Consistent with these toxicophoric structural features, TMFol, which bears no hydroxy moieties in ring A and three methoxys in ring B, was shown here to be devoid of mutagenic properties in the Ames test. Furthermore, the observed absence of detrimental effects of TMFol on murine body weight or organ pathology augurs well for its safety profile. Nevertheless, the putative safety of TMFol needs to be elucidated carefully in further preclinical experiments.
In summary, the properties of TMFol described here support the notion that chemical modification of the flavonol structure based on existing, albeit scarce, information on the relationship between flavonoid structure and chemopreventive activity or toxicity may generate useful cancer chemopreventive agents. It is conceivable that, with further acquisition of knowledge of the important molecular targets of flavonoids and their structure-activity relationships, the flavonol structure can be optimized even more, beyond TMFol. Nevertheless, in the light of its favorable pharmacological profile described here, TMFol deserves additional preclinical investigation to help adjudge whether it is worthy of advancement to the stage of clinical development. TMFol should be studied for chemopreventive efficacy in other rodent carcinogenesis models. It might also be propitious to investigate 20 combinations of TMFol together with agents, such as cyclooxygenase inhibitors, which engage complimentary chemoprevention mechanisms.
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